Pfizer (NYSE:PFE)

Pfizer

4 UBS Most Preferred Pharmaceutical Stocks That Pay Big Dividends

Needless to say, the health care sector, especially pharmaceuticals and biotech, have taken a rhetorical beating from politicians looking to force the blame for high drug prices on some of the ...
Read Full Story »
white pills

Short Sellers Take Mixed Stance on Major Pharma

The short interest data have been released for the May 13 settlement date. Pharmaceutical companies usually are involved in a lengthy process in getting their drug candidates to market through ...
Read Full Story »
ThinkstockPhotos-481735362

The 5 Most Shorted NYSE Stocks: Short Sellers Pick a New Favorite

As the time of “sell in May and go away” arrived, it seems the short sellers were neither strongly for nor against the notion, as least as far as the ...
Read Full Story »
graph

8 Stocks on the Move After ASCO Cancer Abstracts

The American Society of Clinical Oncology (ASCO) is in the process of setting up for its annual meeting in Chicago. In this meeting, companies and cancer drug developers will share ...
Read Full Story »
Pfizer

Pfizer Pays $5.2 Billion for Anacor

Pfizer Inc. (NYSE: PFE) announced Monday that it has reached a definitive agreement to acquire Anacor Pharmaceuticals Inc. (NASDAQ: ANAC) for $99.25 a share in cash. Net of Anacor's cash ...
Read Full Story »
child with cancer

ASCO Could Make or Break These 7 Cancer Drug Trials

It is now getting close to the middle of May, and that means one thing for biotech investors. The king of biotech and pharma events is about to take place. ...
Read Full Story »
white pills

Major Pharma Short Interest Continues to Recede

The short interest data have been released for the April 29 settlement date. Pharmaceutical companies usually are involved in a lengthy process in getting their drug candidates to market through ...
Read Full Story »
Gold Mine

The 5 Most Shorted NYSE Stocks: Short Sellers Still in Retreat

As the markets reached all-time highs last month, the short sellers were in retreat, judging by the moves in the most heavily shorted stocks traded on the New York Stock ...
Read Full Story »
analysis

Top Analyst Upgrades and Downgrades: Bats, Eli Lilly, Gap, Hasbro, JD.com, Nike, Pfizer, SolarCity and More

Stocks were indicated to open higher on Tuesday in what looks like a broad rally. With the Dow still down about 500 points from the April highs, investors still seem ...
Read Full Story »
running

4 Top Blue Chip Dividend Stocks to Buy and Hold Forever

With the presumptive candidates for the presidential election in place, one thing investors now need to contemplate is what stocks will do better under a Clinton or a Trump presidency. One ...
Read Full Story »
Prescription drugs

Analysts Adjust Predictions on Medivation Buyout Price

One time when missing earnings estimates doesn't matter much is when there is bidding war for the company. That's the position that Medivation Inc. (NASDAQ: MDVN) found itself in after ...
Read Full Story »
Medicine pills

3 Big Pharma Stocks With Credible Threats to Their Blockbusters

A pharmaceutical company could face a threat to one of its products for a number of reasons, ranging from an improved formulation, a new drug approval to simply a patent expiry and the ...
Read Full Story »
market crash

The 5 Dow Stocks That Defied the Selling Tuesday

May 3, 2016: Markets opened lower Tuesday following some overnight weakness in overseas markets resulting from weak data on trade from both China and Europe and a strengthening dollar. Energy ...
Read Full Story »
Pfizer

Pfizer Boosts Guidance With Help From Hospira, Weaker Dollar

When Pfizer Inc. (NYSE: PFE) reported first-quarter 2016 results before markets opened Tuesday, it posted adjusted diluted earnings per share (EPS) of $0.67 and revenues of $13 billion. In the ...
Read Full Story »
coins

What to Expect From Pfizer Earnings

Pfizer Inc. (NYSE: PFE) is scheduled to report its first-quarter financial results before the markets open on Tuesday. Thomson Reuters has consensus estimates calling for $0.55 in earnings per share ...
Read Full Story »